From Proteopedia
(Difference between revisions)
proteopedia linkproteopedia link
|
|
| Line 1: |
Line 1: |
| - | [[Image:2ban.gif|left|200px]] | + | {{Seed}} |
| | + | [[Image:2ban.png|left|200px]] |
| | | | |
| | <!-- | | <!-- |
| Line 9: |
Line 10: |
| | {{STRUCTURE_2ban| PDB=2ban | SCENE= }} | | {{STRUCTURE_2ban| PDB=2ban | SCENE= }} |
| | | | |
| - | '''Crystal structure of HIV-1 reverse transcriptase (RT) in complex with JANSSEN-R157208'''
| + | ===Crystal structure of HIV-1 reverse transcriptase (RT) in complex with JANSSEN-R157208=== |
| | | | |
| | | | |
| - | ==Overview==
| + | <!-- |
| - | In the treatment of AIDS, the efficacy of all drugs, including non-nucleoside inhibitors (NNRTIs) of HIV-1 reverse transcriptase (RT), has been limited by the rapid appearance of drug-resistant viruses. Lys103Asn, Tyr181Cys, and Tyr188Leu are some of the most common RT mutations that cause resistance to NNRTIs in the clinic. We report X-ray crystal structures for RT complexed with three different pyridinone derivatives, R157208, R165481, and R221239, at 2.95, 2.9, and 2.43 A resolution, respectively. All three ligands exhibit nanomolar or subnanomolar inhibitory activity against wild-type RT, but varying activities against drug-resistant mutants. R165481 and R221239 differ from most NNRTIs in that binding does not involve significant contacts with Tyr181. These compounds strongly inhibit wild-type HIV-1 RT and drug-resistant variants, including Tyr181Cys and Lys103Asn RT. These properties result in part from an iodine atom on the pyridinone ring of both inhibitors that interacts with the main-chain carbonyl oxygen of Tyr188. An acrylonitrile substituent on R165481 substantially improves the activity of the compound against wild-type RT (and several mutants) and provides a way to generate novel inhibitors that could interact with conserved elements of HIV-1 RT at the polymerase catalytic site. In R221239, there is a flexible linker to a furan ring that permits interactions with Val106, Phe227, and Pro236. These contacts appear to enhance the inhibitory activity of R221239 against the HIV-1 strains that carry the Val106Ala, Tyr188Leu, and Phe227Cys mutations.
| + | The line below this paragraph, {{ABSTRACT_PUBMED_16302798}}, adds the Publication Abstract to the page |
| | + | (as it appears on PubMed at http://www.pubmed.gov), where 16302798 is the PubMed ID number. |
| | + | --> |
| | + | {{ABSTRACT_PUBMED_16302798}} |
| | | | |
| | ==About this Structure== | | ==About this Structure== |
| Line 31: |
Line 35: |
| | [[Category: Reverse transcriptase]] | | [[Category: Reverse transcriptase]] |
| | [[Category: Rt]] | | [[Category: Rt]] |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 20:03:00 2008'' | + | |
| | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 05:39:53 2008'' |
Revision as of 02:39, 28 July 2008
Template:STRUCTURE 2ban
Crystal structure of HIV-1 reverse transcriptase (RT) in complex with JANSSEN-R157208
Template:ABSTRACT PUBMED 16302798
About this Structure
2BAN is a Protein complex structure of sequences from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.
Reference
Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains., Himmel DM, Das K, Clark AD Jr, Hughes SH, Benjahad A, Oumouch S, Guillemont J, Coupa S, Poncelet A, Csoka I, Meyer C, Andries K, Nguyen CH, Grierson DS, Arnold E, J Med Chem. 2005 Dec 1;48(24):7582-91. PMID:16302798
Page seeded by OCA on Mon Jul 28 05:39:53 2008
